Related Experiment Video
Updated: Apr 12, 2026
11:35
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
58.9K
Functional clinical outcomes in multiple sclerosis: Current status and future prospects.
Rana Karabudak1, Maurice Dahdaleh2, Mohammed Aljumah3
1Hacettepe University Hospitals, Dept. of Neurology, Neuroimmunology Unit, Ankara, Turkey.
Multiple Sclerosis and Related Disorders
|May 27, 2015
Summary
The Expanded Disability Status Scale (EDSS) is limited for measuring multiple sclerosis (MS) disability. Composite measures like the MS Functional Composite (MSFC), potentially enhanced with the Symbol Digit Modality Test, offer more sensitive assessments.
Area of Science:
- Neurology
- Clinical Trials
- Disability Assessment
Background:
- The Expanded Disability Status Scale (EDSS) is the primary tool for assessing multiple sclerosis (MS) disability.
- The EDSS is heavily weighted towards ambulation, potentially limiting its sensitivity to broader neurological impairments.
- Composite endpoints offer a more comprehensive evaluation of MS-related disability by incorporating multiple functional domains.
Purpose of the Study:
- To evaluate the utility of composite endpoints for measuring disability in multiple sclerosis (MS).
- To explore the potential improvement of the MS Functional Composite (MSFC) by replacing the Paced Auditory Serial Addition Test (PASAT) with the Symbol Digit Modality Test (SDMT).
- To consider the integration of quality of life (QoL) measures alongside composite endpoints for a holistic patient assessment.
Main Methods:
- Review of existing clinical trial methodologies and assessment tools for multiple sclerosis (MS).
- Analysis of the components of the MS Functional Composite (MSFC), including the 25-ft walk, 9-hole peg test, and PASAT.
- Consideration of alternative cognitive tests, specifically the Symbol Digit Modality Test (SDMT), for potential inclusion in the MSFC.
Main Results:
- Composite endpoints, such as the MSFC, provide a more sensitive measure of MS disability than the EDSS alone.
- Replacing PASAT with SDMT in the MSFC may enhance its clinical utility and patient acceptance.
- Disease-modifying therapies show potential in delaying relapses, underscoring the need for precise disability assessment tools.
Conclusions:
- Composite measures like the MSFC are valuable for assessing disability in multiple sclerosis (MS) clinical trials and practice.
- The MSFC, potentially modified with the SDMT, offers a more sensitive and comprehensive evaluation of MS-related disability.
- Integrating disease-specific QoL measures with composite endpoints provides a more complete picture of treatment efficacy and disease progression in MS.
